Drug Target Review

APRIL 9, 2024

Initial works from the lab concentrated on exploring the role of replicative stress in cancer and ageing, for which the group combined cell biology, mouse models and drug development projects. Among other discoveries, the group developed inhibitors of the ATR kinase and showed their potential for cancer therapy.

RNA 64

RNA Cell Biology Clinical Development Disease 64

Alta Sciences

JANUARY 31, 2025

It owned the societal name of the Canadian Association for Research on Drug Safety. As experts in early-phase drug development , from discovery through Phase II clinical research , we at Altasciences can share with STC members our accumulated knowledge and experience, and provide mentorship for future toxicologists.

Cell Biology 52

Cell Biology Pharmaceutical Companies Clinical Research Government 52

DrugBank

JUNE 27, 2023

The general notion is that patients should be viewed individually, rather than strictly as members of some larger general population, and that their specific genetic background, environment, and lifestyle choices should be considered throughout drug development to the point of treatment and continuing patient care.

Disease 98

Disease Treatment Drugs Clinical Trials 98

NIH Director's Blog: Drug Development

SEPTEMBER 20, 2018

That’s good news for the future development of drugs designed to target those receptors ever more precisely, getting them to work better and with fewer side effects. 2] G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs? 2018 Jun;558(7711):553-558. [2] Mol Pharmacol.

Laboratories 52

Laboratories Research Regulations Drugs 52

Codon

APRIL 9, 2024

sweet wormwood), from which artemisinin, the antimalarial drug, was first isolated. Artemisinin-based drugs work by causing Plasmodium proteins to unfold and by inhibiting new proteins from folding properly, which eventually destroys the parasite. ’s Good Manufacturing Practice standards for drug production.

Drugs 140

Drugs Science Research Doctors 140

New Drug Approvals

JANUARY 9, 2024

As such, it has been proposed that inhibiting CDK7 would provide a potent means of inhibiting cell cycle progression, which may be especially relevant given that there is compelling evidence from gene knockout studies in mice for lack of an absolute requirement for CDK2, CDK4 and CDK6 for the cell cycle at least in most cell types (M alumbres et al.,

Production 62

Production DNA RNA Regulations 62

Broad Institute

OCTOBER 11, 2023

By Allessandra DiCorato October 11, 2023 In 2011, Robert Manguso was working in a cell biology lab when his mother was diagnosed with Merkel cell carcinoma, a rare and aggressive skin cancer. They are used to treat cancers including melanoma and non-small cell lung cancer, but work only for a small fraction of patients.

Research 137

Research Immune Response Clinical Trials Therapies 137

NIH Director's Blog: Drug Discovery

APRIL 11, 2017

Not only does this discovery raise hope for better treatments for many parasitic and bacterial diseases, it highlights the value of screening peptides in the search for ways to treat conditions that do not respond well—or have stopped responding—to more traditional chemical drug compounds. All of their hard work came up empty. Nat Commun.

Small Molecule 52

Small Molecule Science Drug Development Disease 52

Drug Target Review

JANUARY 16, 2025

What are macrocycles and why are they interesting for drug discovery? Traditionally, drug discovery has focused on small-molecule therapeutics, typically with a molecular weight of less than 500 Daltons. 2 Typically, small-molecule drugs target active sites buried inside proteins. 8 Why are there not more macrocyclic drugs?

Drug Development 52

Drug Development Small Molecule Drugs FDA Approval 52

Drug Target Review

APRIL 1, 2025

Founded in 2021, SynaptixBio is working to develop therapies for TUBB4A leukodystrophies – a group of rare and severe neurological disorders. Co-founder and CEO Dr Dan Williams brings over 20 years of experience in biochemistry and drug development, with a strong background in research and clinical trials.

Disease 52

Disease Therapies Clinical Trials Cell Biology 52

Broad Institute

NOVEMBER 21, 2024

Researchers identify source of a brain cancer’s deadly transformation By Corie Lok November 21, 2024 Breadcrumb Home Researchers identify source of a brain cancer’s deadly transformation Slow-growing glioma tumors become more aggressive when their cells shift identities and acquire new genetic mutations.

Research 124

Research Medical Schools DNA Hospitals 124

SugarCone Biotech

MAY 28, 2019

Learnings regarding immune geography and cell:cell contact are increasingly important as we consider how best to advance cell therapies for diverse hematologic malignancies and solid tumors ( www.aletabio.com ). This was an interesting finding and one that I think remains under-appreciated by the immuno-oncology drug development field.

Immune Response 52

Immune Response Therapies Engineering Drug Development 52